Chemomab Secures FDA Alignment for Single Pivotal Phase 3 Trial of Nebokitug in PSC, Extends Cash Runway
Summary
Chemomab Therapeutics announced successful FDA alignment for a single pivotal Phase 3 trial of nebokitug in PSC, a significant de-risking event, alongside financial results extending its cash runway through Q1 2027.
Key Events
-
FDA Alignment on Phase 3 Design for Nebokitug
The company completed a successful End-of-Phase 2 meeting with the FDA, achieving alignment on a clear and efficient pathway for potential regulatory approval of nebokitug in Primary Sclerosing Cholangitis (PSC) based on a single pivotal Phase 3 trial. The trial will use a primary composite endpoint of well-characterized clinical events associated with disease progression.
-
Extended Cash Runway
Chemomab reported cash, cash equivalents, and short-term bank deposits of $10.4 million as of December 31, 2025. This cash position is expected to fund operations through the end of the first quarter of 2027.
-
Positive Phase 2 Data Reinforcement
Results from the Phase 2 SPRING trial for nebokitug in PSC were published in the American Journal of Gastroenterology and featured in multiple scientific presentations, reinforcing its positive safety profile and disease-modifying potential.
-
Advancing Strategic Partner Discussions
Discussions with potential strategic partners are continuing to advance as the company progresses activities required for the timely initiation of the Phase 3 trial in PSC.
Analysis
Chemomab Therapeutics has achieved a critical milestone by securing FDA alignment on a clear and efficient pathway for nebokitug's Phase 3 trial in Primary Sclerosing Cholangitis (PSC). This agreement for a single pivotal trial, utilizing a clinical event-driven composite endpoint, significantly de-risks the development program and provides a streamlined path towards potential regulatory approval. For a clinical-stage biotech, this regulatory clarity is a major positive catalyst. Additionally, the company has extended its cash runway through the first quarter of 2027, providing financial stability to advance its lead program.
At the time of this filing, CMMB was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $1.35 to $5.96. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.